All News #Library
Rare Diseases
Intellia Therapeutics Reports Extended Phase 1 Results
25 Sep 2025 //
GLOBENEWSWIRE
Intellia Therapeutics To Unveil Extended Phase 1 Data
22 Sep 2025 //
GLOBENEWSWIRE
Intellia reports positive 2-year data on Nexiguran at PNS Meeting
18 May 2025 //
GLOBENEWSWIRE
Intellia starts late-stage test of CRISPR for rare swelling disease
08 Oct 2024 //
BIOPHARMADIVE
Intellia Receives European Union Orphan Drug Designation for NTLA-2002
14 Nov 2023 //
GLOBENEWSWIRE

Market Place
Sourcing Support